HK Stock Market Move | AKESO (09926) rose nearly 6% during trading, and Akeso Health Sciences saw an 82% surge on its first day of listing. AKESO is one of the cornerstone investors.

AKESO (09926) rose nearly 6% during trading, rising 4.87% to HK$95.75 at the time of writing, with a turnover of HK$8.32 billion. On the news front, Pharmaron-B (02617) was listed today, rising over 82% at one point, with a total market value exceeding HK$9 billion. It is reported that Pharmaron-B issued a total of 15.281 million shares, raising approximately HK$161 million. Five cornerstone investors, Jiangbei Medical, AKESO, Washington Hing, Pharmstone Horizon, and Kiho Anhe, collectively subscribed to HK$130 million in the company's shares. According to the prospectus, Pharmaron-B is a clinical demand-driven biopharmaceutical company in the registration clinical stage, focusing on the discovery and development of small molecule innovative therapies for tumors, inflammation, and cardiovascular metabolic diseases. The company's core product, Tinengotinib, is a unique MTK inhibitor discovered and developed independently in the registration phase of clinical trials, targeting the treatment of several recurring or refractory solid tumors. As of June 4, 2025, Tinengotinib is undergoing two key/registration clinical trials for the treatment of bile duct cancer progression after previous treatment with FGFR inhibitors, one in China and the other a cross-regional clinical trial involving the United States.